American Century Companies Inc. Sells 341,642 Shares of Lantheus Holdings, Inc. $LNTH

American Century Companies Inc. lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 32.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 721,422 shares of the medical equipment provider’s stock after selling 341,642 shares during the quarter. American Century Companies Inc. owned 1.09% of Lantheus worth $37,002,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Hantz Financial Services Inc. boosted its holdings in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Lantheus during the second quarter worth approximately $26,000. First Horizon Corp bought a new position in Lantheus during the 3rd quarter worth $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the 2nd quarter worth $36,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in Lantheus in the 3rd quarter valued at $59,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, February 26th. Truist Financial increased their price target on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Citizens Jmp upped their target price on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a report on Tuesday, February 24th. Finally, JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Stock Performance

Shares of Lantheus stock opened at $72.56 on Friday. The business’s fifty day simple moving average is $69.11 and its 200 day simple moving average is $60.90. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $111.29. The firm has a market capitalization of $4.69 billion, a P/E ratio of 21.53 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.